Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
July 18, 2023
Assignees:
MEMORIAL SLOAN-KETTERING CANCER CENTER, THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.
Type:
Grant
Filed:
August 18, 2017
Date of Patent:
July 18, 2023
Assignee:
BEIGENE SWITZERLAND GMBH
Inventors:
Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo
Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
July 18, 2023
Assignee:
The Feinstein Institutes for Medical Research
Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
Type:
Grant
Filed:
March 5, 2020
Date of Patent:
June 27, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
Abstract: The present invention provides a pharmaceutical composition and a treatment method to be combined with radiotherapy, for treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 blockade and a PI3K? ? inhibitor, and it has excellent effects of inhibiting tumor and enhancing immunity by combining the PD-1 blockade and PI3K? ? inhibitor with radiotherapy, compared to single therapy of each therapeutic agent.
Type:
Grant
Filed:
July 6, 2020
Date of Patent:
June 13, 2023
Assignee:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
Type:
Grant
Filed:
September 4, 2020
Date of Patent:
June 13, 2023
Assignee:
UCB BIOPHARMA SRL
Inventors:
James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Munro
Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
June 13, 2023
Assignee:
University of Louisville Research Foundation, Inc.
Inventors:
John W. Eaton, Kavitha Yaddanapudi, Chi Li
Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
June 6, 2023
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Sayantan Mitra, Nicole G. Lapuyade, Hikmat Haizar Assi, Madan M. Paidhungat, Dylan L. Daniel, Erwan Le Scolan, Walter A. Bogdanoff, Na Cai, Hsin Wang, Alexey Yevgenyevich Berezhnoy
Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
May 30, 2023
Assignee:
Tesaro, Inc.
Inventors:
Keith W. Mikule, Kaiming Sun, Jing Yu Wang, Zebin Wang
Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
Abstract: The present disclosure relates to chimeric engulfment receptor molecules, host cells modified to include the phagocytic engulfment molecules, and methods of making and using such receptor molecules and modified cells.
Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.
Abstract: The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.
Inventors:
Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie K. Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Zeren Gao
Abstract: Compositions and methods are provided for classification and treatment of MYC-driven cancers, i.e. causally dependent on MYC as a result of, over-expression of MYC, constitutive expression of MYC, chromosomal translocation resulting in overactive MYC, and the like. Specifically, the methods comprising determining the MYC status of the cancer, and in a cancer that is determined to be driven by MYC activation, administering a composition of an effective dose of one or both of activated natural killer (NK) cells and a type 1 interferon.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
May 16, 2023
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Srividya Swaminathan, Dean W. Felsher, Holden Terry Maecker
Abstract: There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.
Type:
Grant
Filed:
November 27, 2020
Date of Patent:
May 2, 2023
Assignee:
GI INNOVATION, INC.
Inventors:
Myoung Ho Jang, Su Youn Nam, Young Jun Koh, Young-Gyu Cho
Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
April 4, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
Abstract: Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
March 7, 2023
Assignees:
The University of Chicago
Inventors:
Yusuke Nakamura, Jae-Hyun Park, Sachiko Yoshimura, Tetsuro Hikichi